Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure

A Simonini, K Chang, P Yue, C S Long, B M Massie

Abstract

Objective—To determine whether heart failure in rats is associated with altered expression of the skeletal muscle sarcoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA).

Methods—SERCA protein and mRNA were examined in the soleus muscles of eight female rats with heart failure induced by coronary artery ligation, six weeks after the procedure (mean (SEM) left ventricular end diastolic pressure 20.4 (2.2) mm Hg) and in six sham operated controls by western and northern analyses, respectively.

Results—SERCA-2a isoform protein was reduced by 16% (112 000 (4000) \(v\) 134 000 (2000) arbitrary units, \(p < 0.001\)), and SERCA-2a messenger RNA was reduced by 59% (0.24 (0.06) \(v\) 0.58 (0.02) arbitrary units, \(p < 0.001\)). Although rats with heart failure had smaller muscles (0.54 mg/g body weight), no difference in locomotor activity was observed.

Conclusions—These results may explain the previously documented abnormalities in calcium handling in skeletal muscle from animals with the same model of congestive heart failure, and could be responsible for the accelerated muscle fatigue characteristic of patients with heart failure.


(Heart 1999;81:303–307)

Keywords: skeletal muscle; gene expression; heart failure; calcium-ATPase

Exercise intolerance is a common complaint in patients with congestive heart failure and is often their major limiting symptom. Although impaired cardiac output and peripheral blood flow may be partially responsible for this physiological limitation, many studies have identified abnormalities of skeletal muscle and these may also play an important role. These include atrophy, altered fibre type composition, and impaired oxidative metabolism. These observed abnormalities are not, however, likely to fully explain the pattern of muscle fatigue in patients, which is striking in its rapidity and severity and appears to reflect impaired excitation–contraction coupling. In this regard, Perreault et al found that in rats with heart failure induced by coronary artery ligation, skeletal muscle fibres showed accelerated fatigue during electrical stimulation, associated with abnormal calcium transients characterised by a reduced amplitude and delayed rise and decline.

As reviewed by Arai et al, similar abnormalities in calcium handling have been observed in cardiac muscle and have been associated with reduced expression of the sarcoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA), which is responsible for calcium reuptake following contraction but also indirectly determines the amount of calcium availability for force development in both cardiac and skeletal muscle. Since we have recently observed that there are alterations in contractile protein and oxidative enzyme expression in skeletal muscle in rats with heart failure, we hypothesised that SERCA expression might also be downregulated, thus providing a possible mechanism for the changes in muscle function. This study was therefore undertaken to determine whether heart failure in rats is associated with altered expression of the skeletal muscle SERCA.

Methods

EXPERIMENTAL MODEL

The rat coronary ligation model was employed to induce heart failure using previously described procedures. After acclimatisation for one week in the animal facility, female Sprague-Dawley rats weighing 240–260 g were anaesthetised with 2% isoflurane, intubated, and maintained on a Harvard rodent ventilator. A left thoracotomy was performed at the fifth intercostal space and, while the heart was exteriorised, the main left coronary artery was ligated 1–2 mm from its origin with a 7-0 purse string suture. In the infarct group, operative mortality was 30% and overall survival at the time of study six weeks postsurgery was 50%. All sham operated rats survived. Postoperatively, rats were housed in two-animal acrylic cages and received food and water ad libitum.

HAEMODYNAMIC MEASUREMENTS

At the time of study, rats were lightly anaesthetised with ketamine (70 mg/kg) plus xylazine (10 mg/kg), and the right carotid artery was cannulated with a 2 F micromanometer tipped catheter (Millar Instruments, Houston, Texas, USA). Under continuous pressure monitoring, the catheter was advanced retrogradely into the left ventricle and pressures were recorded. Only animals with left ventricular end diastolic
pressures of more than 15 mm Hg were included in the heart failure group (n = 8). Infarcted animals with lower left ventricular end diastolic pressures were not used in this study.

**ACTIVITY MONITORING**

Locomotor activity of matched heart failure and sham control animals was measured eight weeks after surgery by photocell monitoring, using our previously described techniques. In brief, animals were placed into an open field environment (Opto-Varimex Minor, Columbus Instruments, Columbus, Ohio, USA) measuring 16.5 × 16.5 inches (42 × 42 cm), equipped with 15 photocell beams in each direction located 4 cm off the cage floor. Interruptions of photocell beams were cumulatively computer registered in 10 minute intervals over a 12 hour overnight period, one to three days before the animals were killed.

**MUSCLE HARVESTING**

With animals still anaesthetised, the hind limbs were dissected and the left soleus muscle was excised and quickly frozen in precooled isopentane before storage in liquid nitrogen for subsequent protein analysis. The contralateral muscles were then excised, snap frozen in liquid nitrogen, and stored for RNA analysis.

**IMMUNODETECTION OF SERCA USING SOLEUS MUSCLE HOMOGENATES**

Frozen soleus muscles were thawed and homogenised with 4× volume of phosphate buffer containing protease inhibitors (ethylenediaminetetra-acid (EDTA) 2 mM, leupeptin 2 µg/ml, aprotinin 2 µg/ml, and phenylmethanesulphonyl fluoride (PMSF) 0.5 mM). Protein concentration of the muscle homogenates was determined by Bradford protein assay. Samples were incubated at room temperature for 30 minutes in 2× Laemmli buffer (Sigma, St Louis, Illinois, USA) and separated using a 10% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. Each lane was loaded with 2 µg protein. The electrophoresis buffer consisted of 50 mM Tris, 150 mM glycine, and 0.1% SDS. Separating gel was prepared with 2% (wt/vol) acrylamide, and 0.1% (wt/vol) N,N'-methylene-bis-acrylamide in 100 mM Tris, 300 mM glycine, and 0.1% SDS.

After electrophoresis, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane. The gels were stained when the transfer was completed using Coomassie blue to evaluate transfer efficiency. Membranes were incubated at 4°C overnight in blocking buffer (TBS; pH 7.5) which contained 20 mM Tris/Cl, 0.9% NaCl, and was supplemented with 5% bovine albumin (fraction V, Sigma). Membrane was then incubated at room temperature for two hours with primary antibody, a polyclonal antibody (1/1000) against rabbit sarcoplasmic reticulum Ca2+-ATPase-2a isoform, which was kindly provided by Dr J Lytton. After washing with TBS containing 0.1% Tween, the membrane was incubated with 125I labelled secondary antibodies for one hour at room temperature. The protein bands bound to the antibodies were visualized using autoradiography by exposing x ray film (Kodak XOMAT) to the 125I labelled membrane overnight at −80°C. The density of the autoradiograph was quantified using a scanning densitometer.

**NORTHERN BLOT ANALYSIS**

Total cellular RNA was isolated by the method of Chomczynski and Sacchi. RNA was quantified by absorbance at 260 nm and its integrity was determined by examining the 28S and 18S rRNA bands in ethidium bromide stained agarose gels. Total RNA (15 µg/lane) was separated by denaturing agarose gel electrophoresis, subjected to alkali pretreatment, transferred to nylon membranes, and cross linked by ultraviolet irradiation. β Myosin heavy chain (β-MHC) mRNA was detected by hybridisation to a 40 base oligodeoxyribonucleotide probe (Oncogene Science Inc, Uniondale, New York, USA) complementary to a unique 3’ untranslated region of rat β-MHC mRNA. SERCA2 mRNA was detected by hybridisation to a fragment of the cDNA encoding rat SERCA-2a (courtesy of Dr W Dillmann, University of California, San Diego). This 2a isoform is found in both rat myocardium and slow twitch skeletal muscle fibre types. To provide an internal standard, all blots were hybridised with a riboprobe complementary to 18S ribosomal RNA (Ambion Inc, La Jolla, California, USA). The cDNA and 18S RNA probes were prepared and radiolabelled by random primed labelling and T7 RNA
polymerase, respectively, and hybridised as previously described. All blots were exposed to Hyperfilm (Amersham, Uniondale, New York, USA) at −80°C. Exposure time was determined by preliminary experiments so as to provide quantitation of densitometric signals within the linear range of detection. For comparison, each blot contained RNA from both heart failure and control animals. Ribosomal (18S) RNA signals were unchanged relative to controls in the heart failure group. SERCA2 mRNA was quantified by scanning densitometry and software (Scan Analysis, Ofoto, Berkeley, California, USA) which used background subtraction and 18S signals for normalisation and quantitation.

STATISTICAL ANALYSIS

The significance of intergroup differences in quantitative mRNA and protein variables was examined by Student’s t tests. Data are presented as means (SEM).

Results

HAEMODYNAMIC AND ACTIVITY MEASUREMENTS

Haemodynamic and weight data are shown in table 1. The heart failure group consisted of eight rats with myocardial infarctions and left ventricular end diastolic pressures ≥ 15 mm Hg (mean 20.4 (2.4) mm Hg). The control group consisted of six animals, all of which had a left ventricular end diastolic pressure of ≤ 8 mm Hg (mean 5.2 (0.5)). In addition to raised left ventricular end diastolic pressures, the heart failure group had a 40% reduction in maximum dP/dt compared with the control group (7211 (492) v 11 333 (551) mm Hg/s, p < 0.001). The lower soleus muscle weight in the heart failure rats (156.0 (5.0) mg v 178.5 (3.4) mg), even after correction for body mass (0.55 (0.02) v 0.66 (0.01) mg/g, p < 0.001), is consistent with skeletal muscle atrophy in the heart failure group. Overnight activity was not different between the heart failure rats and controls (3810 (360) v 3885 (240) counts/h).

SOLEUS PROTEIN AND RNA ANALYSIS

Figures 1 and 2 shows the result of soleus SERCA2 protein assays. The soleus muscles from the heart failure rats contained 16% less SERCA2 protein than those from the controls, as determined by densitometry (mean 112 000 (4000) v 134 000 (2000) arbitrary units, p < 0.001). This reduction persisted when soleus SERCA2 protein content was normalised to that of myosin heavy chain, as determined by SDS-PAGE (2.57 (0.04) v 2.79 (0.02) arbitrary units, p < 0.001).

The results of northern blots are shown in fig 3. Heart failure was associated with a greater than 50% decrease in SERCA2 mRNA in the soleus muscles (0.24 (0.06) v 0.58 (0.02) arbitrary units for the shams, p < 0.001) when standardised to the content of 18S RNA per lane. The content of soleus mRNA encoding β-MHC in heart failure rates was also significantly reduced when compared with that in sham rats. There were disproportionate reductions in SERCA2 mRNA (> 50%) and protein expression (16%) in skeletal muscle during heart failure.

Discussion

In this study, a well established experimental model of congestive heart failure was used to demonstrate that chronic left ventricular dysfunction in rats is associated with alterations in the level of expression of specific RNA transcripts encoding the sarcoplasmic reticulum ATPase, as well as its cognate protein. The observed reduction in calcium transport gene expression corresponded with a decrease in mRNA encoding for β-MHC, the predominant contractile protein in the soleus, similar to our observations in a previous study. This new finding not only extends our previous findings of reduced expression of contractile proteins and oxidative enzymes in skeletal muscle, but also provides additional insight into the mechanisms contributing to skeletal muscle dysfunction in clinical heart failure. As noted in our previous study, the comparable activity levels of...
heart failure and control rats makes deconditioning an unlikely explanation for the muscle changes.

The present results add to the list of known derangements in skeletal muscle that may contribute to exercise intolerance in congestive heart failure. Several previous studies have shown that heart failure is associated with muscle atrophy at both the organ and fibre level. In addition, there is a shift in muscle fibre type distribution from slow twitch type I (β-MHC) fibres to fast twitch type II fibres, and within the type II subgroup, from the more oxidative Iia fibres to the more glycolytic Iib and Iib phenotypes. These changes occur with a concomitant reduction in muscle oxidative enzyme activity across all fibre types.

Although these previously reported abnormalities may lead to accelerated acidosis and cause easy fatigability with exercise, the degree of these changes is not as prominent as the pattern of fatigue, which appears to be disproportionately severe and rapid. For instance, in three studies conducted in men with congestive heart failure, we found that during 30 seconds of repetitive knee extensions force decreased by 40% to 50%. In contrast, muscle strength was relatively preserved, muscle size was reduced by only 15%, and there was a 20% reduction in the proportion of type I fibres. This discrepancy suggests that other factors may also contribute to muscle fatigue in heart failure.

In addition to alterations in myosin heavy chain gene expression shown in this and previous investigations, a possible mechanism contributing to the muscle fatigue of heart failure is altered intracellular calcium handling. Since calcium plays a vital role in muscle contraction, relaxation, and fatigue, reduced calcium availability could contribute to the observed functional abnormalities and at least partially explain the discordance between changes in strength and fatigue with exercise in heart failure patients. Indeed, Perreault et al previously reported a decline in amplitude and a prolongation of duration of the cytosolic calcium transient, with a more rapid decline in the calcium signal during repetitive twitch or tetanic stimulation in the extensor digitorum muscles from rats with postinfarction heart failure. As might be expected because of the critical role of calcium in excitation–contraction coupling, these changes were associated with diminished force development and a more rapid decline in force during stimulation. Taken together, these findings suggest that a defect in calcium transport or protein regulation in the rat and accelerated muscle fatigue in both human and experimental congestive heart failure. The similarity of many of the abnormalities in skeletal muscle to those observed in the failing heart is noteworthy. Further research into the signals for altered gene expression in skeletal muscle may not only help explain the mechanisms of exercise intolerance but also provide insight into the pathophysiology of myocardial dysfunction in heart failure.

LIMITATIONS
Our study has several limitations. First, we did not measure muscle function in these animals. However, both force development and relaxation were shown to be abnormal in the previously cited study by Perreault et al, using the same model of heart failure. A second limitation is the lack of corresponding measurements of sarcoplasmic reticular function in the soleus muscles. Again, the disturbances of calcium transients observed by Perreault et al during muscle stimulation in rats with heart failure are consistent with abnormalities of calcium handling proteins. Also, we did not examine the expression of other calcium handling proteins that may play a role in SERCA regulation and function, nor did we examine muscles other than the soleus, although abnormalities in this almost exclusively slow twitch muscle would be expected to play a particularly important role in early fatigue.

CONCLUSION
We have shown that heart failure in the rat is associated with a decrease in the expression of SERCA2 in skeletal muscle at both mRNA and protein level. This extends our previous observation of altered contractile protein and oxidative enzyme expression in this setting, and could explain both previous observations of abnormal skeletal muscle calcium handling in the rat and accelerated muscle fatigue in both human and experimental congestive heart failure. The similarity of many of the abnormalities in skeletal muscle to those observed in the failing heart is noteworthy. Further research into the signals for altered gene expression in skeletal muscle may not only help explain the mechanisms of exercise intolerance but also provide insight into the pathophysiology of myocardial dysfunction in heart failure.

This work was supported in part by grants 5T32-GM07456 (AS) and PO1-HL25847 (CSL) from the National Heart, Lung and Blood Institute, Bethesda, Maryland; the Department of Veterans Affairs Research Service, Washington, DC (CSL, BMM); and grants 92-41 (AS) and 96-79 (PY) from the California Affiliate of the American Heart Association, Burlingame, California.

Skeletal muscle gene expression in heart failure


20 Tyler DD, Tessel RE. A new device for the simultaneous measurement of locomotor and stereotypic frequency in mice. Psychopharmacology 1979;64:285–90.


Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure

A Simonini, K Chang, P Yue, C S Long and B M Massie

*Heart* 1999 81: 303-307
doi: 10.1136/hrt.81.3.303

Updated information and services can be found at:
http://heart.bmj.com/content/81/3/303

These include:

**References**

This article cites 24 articles, 15 of which you can access for free at:
http://heart.bmj.com/content/81/3/303#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Heart failure (565)
- Hypertension (3006)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/